Zepbound vs. Orlistat
Zepbound and Orlistat approach weight management differently. Zepbound, a GLP-1 and GIP receptor agonist, reduces appetite and slows gastric emptying for substantial weight loss. Orlistat, a lipase inhibitor, blocks fat absorption, resulting in modest weight loss. Zepbound’s side effects include nausea, while Orlistat is associated with gastrointestinal issues like oily stools. Zepbound’s cost is $1,125, whereas Orlistat is affordable at $100/month. Neither drug currently faces shortages.
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Blocks the breakdown and absorption of dietary fat in the intestines. Unabsorbed fat is excreted in the stool, reducing calorie intake and promoting weight loss.
Common Side Effects
Oily or fatty stools, frequent bowel movements, flatulence with discharge, and abdominal discomfort.
Serious Potential Side Effects
Rare liver damage and malabsorption of fat-soluble vitamins (A, D, E, K), kidney problems, and severe allergic reactions